China restricts opioid in tighter
painkiller controls
Send a link to a friend
[August 08, 2019]
BEIJING (Reuters) - China has imposed new
restrictions on the opioid oxycodone, its drug regulator said, as the
country tightens control of its painkillers industry in the battle
against drug addiction.
|
Oxycodone, among the heavy-duty painkillers blamed for the deadly
opioid crisis in the United States, will be classified as a
pyschotropic drug in some formulations and require more approvals to
produce or prescribe them, the National Medical Products
Administration said late on Tuesday.
Oral solid formulations with more than 5 mg of oxycodone per unit
will be categorized as first-class psychotropic drugs from Sept. 1,
the agency said.
Formulations with less than 5 mg of oxycodone per unit, as well as
composite oral solid formulations with buprenorphine and naloxone,
will be categorized as second-class psychotropic drugs at the same
time, it said.
Under current laws, first class pyschotropic drugs are banned from
sale to retail customers, and second class products cannot be sold
to minors.
The laws also require state approvals for pharmaceutical firms to
use first-class psychotropic drugs as active ingredients in their
products, and hospitals can only purchase these products from
suppliers designated by authorities.
[to top of second column] |
Chinese media have voiced concern over oxycodone addiction in the
country. Financial magazine Caixin reporting in March that opioid
users accounted for 38.1% of the 2.5 million people who were known
to have abused drugs in China in 2016.
Liu Xiaodong, a professor at China Pharmaceutical University, said
the tighter controls would help to reduce the illegal use of
oxycodone.
"Many medicines are useful, but abusing them would turn them into
(illicit) drugs," Liu told Reuters.
Narcotics produced in China have become a contentious issue in
relations with the United States.
This month, President Donald Trump accused his Chinese counterpart
Xi Jinping of failing to meet promises to stop the flow of the
synthetic opioid fentanyl into the United States.
(Reporting by Roxanne Liu and Brenda Goh; editing by Darren
Schuettler)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |